CORRECTION

Open Access



Correction to: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran

Manoochehr Karami^{1,2*}, Pegah Ameri², Jalal Bathaei³, Zeinab Berangi², Tahereh Pashaei⁴, Ali Zahiri³, Seved Mohsen Zahraei⁵, Hussein Erfani³ and Koen Ponnet^{6,7}

Erratum

After publication of the original article [1], the authors noticed that the percentages in Table 2 were incorrect.

The correct version of Table 2 is published in this erratum.

Author details

¹Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. ²Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran. ³Deputy for Health, Hamadan University of Medical Sciences, Hamadan, Iran. ⁴Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran. ⁵Center for Communicable Diseases Control, Ministry of Health, Tehran, Iran. ⁶Department of Communication Studies, Ghent University, Ghent, Belgium. ⁷Faculty of Social Sciences, University of Antwerp, Antwerp, Belgium.

Received: 20 September 2017 Accepted: 21 September 2017 Published online: 05 October 2017

Reference

Karami M, et al. Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran. BMC Immunol. 2017;18:42. doi:10.1186/s12865-017-0226-8.

* Correspondence: ma.karami@umsha.ac.ir

¹Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

²Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran



© The Author(s), 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Adverse events	Incidence (per 100 children) Vaccine dose			<i>P</i> -value (1 st and 2 nd dose	<i>P</i> -value (2 nd and 3 rd dose
	1 st dose (2 months) N = 373	2 nd dose (4 months) N = 372	3 rd dose (6 months) N = 374	comparison)	comparison)
Swelling	79(21.2)	50(13.4)	48(12.8)	0.003	0.068
Redness	50(13.4)	30(8.1)	43(11.5)	0.026	0.679
Pain	190(50.9)	143(38.4)	62(16.6)	0.001	0.162
Mild fever	45(12.1)	33(8.9)	63(16.8)	0.068	<0.001
High fever	1(0.3)	0(0)	0(0)	0.388	NA
Drowsiness	83(22.3)	72(19.4)	70(18.7)	0.310	0.725
Anorexia	65(17.4)	51(13.7)	52(13.9)	0.126	1
Restlessness	35(9.4)	115(30.9)	119(31.8)	<0.001	0.766
Vomiting	16(4.3)	19(5.1)	17(4.5)	0.510	0.510
Long-term crying	24(6.4)	16(4.3)	22(5.9)	0.210	0.510
Encephalopathy	0(0)	0(0)	0(0)	NA	NA
Convulsion	0(0)	0(0)	0(0)	NA	NA
History of convulsion	0(0)	1(0.3)	2(0.5)	0.387	0.488
Family history of convulsion	0(0)	14(3.8)	6(1.6)	<0.001	0.074

Table 2 Comparison of the cumulative incidence rates of complications in the first, second and third doses of the vaccination in children

NA not applicable